Cell-based delivery of glucagon-like peptide-1 using encapsulated mesenchymal stem cells

Journal of Microencapsulation

Volumn 30, Issue 4, 2013, Pages 315-324

  Wallrapp, Christine ^a   Thoenes, Eric ^a   Thürmer, Frank ^a   Jork, Anette ^a   Kassem, Moustapha ^b,c   Geigle, Peter ^a  

^a CellMed AG   (Germany)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cell based drug delivery; Encapsulation; GLP 1 CellBeads ; Glucagon like peptide 1; Mesenchymal stem cells

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-37]; NEUROTROPHIN 3; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ARTICLE; CELL ENCAPSULATION; CELL VIABILITY; DRUG DELIVERY SYSTEM; GOOD MANUFACTURING PRACTICE; HEART PROTECTION; HORMONE RELEASE; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STEM CELL; NEUROPROTECTION; NORMAL HUMAN; PRACTICE GUIDELINE;

ALGINATES; ANIMALS; CELL LINE, TUMOR; CELLS, IMMOBILIZED; DRUG CARRIERS; ENDOTHELIAL GROWTH FACTORS; GLUCAGON-LIKE PEPTIDE 1; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEUROTROPHIN 3; RECOMBINANT PROTEINS;

EID: 84877282011     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.726281     Document Type: Article

References (41)

1. Abdallah BM, Haack-Sorensen M, Burns JS, Elsnab B, Jakob F, Hokland P, Kassem M. Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite extensive proliferation. Biochem Biophys Res Comm, 2005;326:527-38 (Pubitemid 39642757)
2. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab, 2009;94: 1843-52
3. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science, 1998;279:349-52 (Pubitemid 28063364)
4. Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology, 1994;134:2156-64 (Pubitemid 24142957)
5. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem, 2006;98:1076-84 (Pubitemid 44128350)
6. Catena R, Santos E, Orive G, Herna'ndez RM, Pedraz JL, Calvo A. Improvement of the monitoring and biosafety of encapsulated cells using the SFGNESTGL triple reporter system. J Control Release, 2010; 146:93-8
7. Chaikof EL. Engineering and material considerations in islet cell transplantation. Annu Rev Biomed Eng, 1999;1:103-27 (Pubitemid 129740007)
8. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes, 1995;44:1126-31
9. De'glon N, Heyd B, Tan SA, Joseph JM, Zurn AD, Aebischer P. Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts. Hum Gene Ther, 1996;7:2135-46 (Pubitemid 26400738)
10. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet, 2006;368:1696-705 (Pubitemid 46048557)
11. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, et al. Glucagon-like peptide-1
12. Receptor is involved in learning and neuroprotection. Nat Med, 2003;9:1173-9
13. Fletcher C, Sawchuk R, Chinnock B, de Miranda P, Balfour HH. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther, 1986;40:281-6 (Pubitemid 16017854)
14. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: Evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci, 1995;7:2294-300
15. Golla R, Seethalam RA. Homogeneous enzyme fragment complementation cyclic AMP screen for GPCR agonists. J Biomol Screen, 2002;7:515-25 (Pubitemid 135752866)
16. Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, Rogers JT, Ovadia H, Lahiri DK. New therapeutic strategies and drug candidates for neurodegenerative diseases: P53 and TNF alpha Inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci, 2004;1035: 290-315 (Pubitemid 40362340)
17. Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: Potential therapeutic benefits beyond glycaemic control? Br J Pharmacol, 2009;157:1340-51
18. Harkavyi A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol, 2010;159:495-501
19. Heile AM, Wallrapp C, Klinge PM, Samii A, Kassem M, Silverberg G, Brinker T. Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Neurosci Lett, 2009;463:176-81
20. Hinke SA, Gelling RW, Pederson RA, Manhart S, Nian C, Demuth HU, McIntosh CH. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucosedependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes, 2002;51:652-61 (Pubitemid 34760172)
21. Hinke SA, Manhart S, Ku?hn-Wache K, Nian C, Demuth HU, Pederson RA, McIntosh CH. [Ser2]-and [SerP2] incretin analogues: Comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo. J Biol Chem, 2004;279:3998-4006 (Pubitemid 38198982)
22. Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: Theoretical and practical applications. Curr Med Res Opin, 2011;27: 547-58
23. Houtgraaf JH, Dejong R, Monkhorst K, Tempel D, Dendekker WK, Kazemi K, Hoefer I, Pasterkamp G, Lewis AL, Stratford PW, et al. Feasibility of intracoronary GLP-1 eluting CellBead infusion in acute myocardial infarction. Cell Transplant,2012;epub ahead of print
24. Klinge PM, Harmening K, Miller MC, Heile A, Wallrapp C, Geigle P, Brinker T. Encapsulated native and Glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease. Neurosci Lett, 2011;497:6-10
25. Meyerrose T, Olson S, Pontow S, Kalomoiris S, Jung Y, Annett G, Bauer G, Nolta JA. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev, 2010;62:1167-74
26. Murua A, Portero A, Orive G, Hernandez RM, Castro M, Pedraz JL. Cell microencapsulation technology: Towards clinical application. J Control Release, 2008;132:76-83
27. Nikolaidis LA, Mankad S, Sokos GG. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation, 2004;109:962-5 (Pubitemid 38282847)
28. Orive G, Tam SK, Pedraz JL, Hallé JP. Biocompatibility of alginate-poly-Llysine microcapsules for cell therapy. Biomaterials, 2006;27:3691-700 (Pubitemid 43670522)
29. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther, 2002;302:881-8 (Pubitemid 34920207)
30. Salem HK, Thiemermann C. Mesenchymal stromal cells: Current understanding and clinical status. Stem Cells, 2010;28:585-96
31. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, Jensen TG, Kassem M. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol, 2002;20:592-6 (Pubitemid 34595153)
32. Smidsrød O, Skja°k-Braek G. Alginate as immobilization matrix for cells. Trends Biotechnol, 1990;8:71-8
33. Sommadossi JP, Bevan R, Ling T, Lee F, Mastre B, Chaplin MD, Nerenberg C, Koretz S, Buhles WC. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis Suppl, 1988;3:507-14
34. Tolar J, Le Blanc K, Keating A, Blazar BR. Concise review: Hitting the right spot with mesenchymal stromal cells. Stem Cells, 2010;28:1446-55
35. Trouche E, Girod Fullana S, Mias C, Ceccaldi C, Tortosa F, Seguelas MH, Calise D, Parini A, Cussac D, Sallerin B. Evaluation of alginate microspheres for mesenchymal stem cell engraftment on solid organ. Cell Transplant, 2010;19:1623-33
36. Vos P, Bucko M, Gemeiner P, Navra'til M, Svitel J, Faas M, Strand BL, Skjak-Braek G, Morch YA, Vikartovská A, et al. Multiscale requirements for bioencapsulation in medicine and biotechnology. Biomaterials, 2009; 30:2559-70
37. Wilson JT, Chaikof EL. Challenges and emerging technologies in the immunoisolation of cells and tissues. Adv Drug Deliv Rev, 2008;60: 124-45 (Pubitemid 350245691)
38. Xiao Q, Giguere J, Parisien M, Jeng W, St-Pierre SA, Brubaker PL, Wheeler MB. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry, 2001;40:2860-9 (Pubitemid 32198288)
39. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, Yarmush ML. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant, 2010;19: 667-79
40. Zhang R, Ma K, Xu L, Wallrapp C, Jonas JB. Intraocular cell-based production of glucagon-like peptide-1 in the anterior chamber. Acta Ophthalmol, 2010;88:348-9
41. Zimmermann U, Thu?rmer F, Jork A, Weber M, Mimietz S, Hillga?rtner M, Brunnenmeier F, Zimmermann H, Westphal I, Fuhr G, et al. Novel class of amitogenic alginate microcapsules for long-term immunoisolated transplantation. Ann N Y Acad Sci, 2001;944:199-215 (Pubitemid 34053307)